Androgenetik Alopesi

Şahin, Gökhan; AYDİN, Fatma; Özdemir, Hilal

doi:10.32708/uutfd.857676

Androgenetik Alopesi

Gökhan ŞAHİN, (Ondokuz Mayıs Üniversitesi, Tıp Fakültesi, Dermatoloji Anabilim Dalı, Samsun, Türkiye)

Hilal ÖZDEMİR, (Ondokuz Mayıs Üniversitesi, Tıp Fakültesi, Dermatoloji Anabilim Dalı, Samsun, Türkiye)

Fatma AYDIN (Ondokuz Mayıs Üniversitesi, Tıp Fakültesi, Dermatoloji Anabilim Dalı, Samsun, Türkiye)

Uludağ Üniversitesi Tıp Fakültesi Dergisi

41 6

Yıl: 2021 Cilt: 47 Sayı: 1 Sayfa Aralığı: 141 - 149 Metin Dili: Türkçe DOI: 10.32708/uutfd.857676 İndeks Tarihi: 29-07-2022

Androgenetik Alopesi

Öz:

Androgenetik alopesi genetik yatkınlığı olan kişilerde farklı patolojik mekanizmalarla ortaya çıkabilen, erkek ve kadınlarda kliniği değişiklik gösterebilen bir saç dökülme şeklidir. Androgenetik alopesi her ne kadar sık görülüyor ve tanısı genellikle kolay koyuluyor olsa da hasta yönetimi için standart bir tedavi rehberi yoktur. Androgenetik alopesi yönetiminde amaç foliküler minyatürizasyonu durdurmak ve saç dansitesini arttırmaktır. Androgenetik alopesi yönetiminde kullanılan tedaviler potasyum iyon kanalı düzenleyicileri (topikal minoksidil ve oral minoksidil), 5α redüktaz inhibitörleri (oral finasterid, topikal finasterid ve oral dutasterid), androjen reseptör antagonistleri (spironolak-ton, siproteron asetat, flutamid, korteksolon 17 alfa propionat ve topikal fluridil), diğer medikal tedaviler (topikal prostoglandin analogları, topikal ketokonazol, topikal melatonin, Wnt/β katenin sinyal yolağı aktivatörleri ve JAK-STAT yolağı inhibitörleri), fiziksel tedaviler (düşük dereceli lazer ışık tedavisi, lazer tedavileri, mikroiğneleme, mezoterapi, PRP ve kök hücre tedavileri), tamamlayıcı tedaviler (saç transplantasyonu, besin takviyeleri ve kamuflaj yöntemleri) ve kombinasyon tedavileridir. Bu derlemede erkek ve kadında androgenetik alopesi yönetiminde güncel tedavi yöntemleri hakkında bilgi verilmesi amaçlanmıştır.

Anahtar Kelime: minoksidil finasterid Androgenetik alopesi patogenez hasta yönetimi

Androgenetic Alopecia

Öz:

Androgenetic alopecia is a form of hair loss that can occur with different pathological mechanisms in people with genetic predisposition, and the clinic may vary in men and women. Although androgenetic alopecia is common and its diagnosis is usually easy, there is no standard treatment guideline for patient management. The purpose of the management of androgenetic alopecia is to stop follicular miniaturization and to increase hair density. Therapies used in the management of androgenetic alopecia are potassium ion channel modifiers (topical minoxidil and oral minoxidil), 5α reductase inhibitors (oral finasteride, topical finasteride and oral dutasteride), androgen receptor antagonists (spironolactone, cyproterone acetate, flutamide, cortexolone 17 alpha propionate solution and topical minoxidil) , other medical treatments (topical prostaglandin analogues, topical ketoconazole, topical melatonin, Wnt / β catenin signaling pathway activators and JAK-STAT pathway inhibitors), physical treatments (low-grade laser light therapy, laser treatments, microneedling, mesotherapy, PRP and stem cell treatments), complementary therapies (hair transplantation, nutritional supplements and camouflage methods) and combination therapies. In this review, it is aimed to provide information about current treatment methods in the management of androgenetic alopecia in men and women.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık

1. Rhodes T, Girman CJ, Savin RC, et al. Prevalence of male pattern hair loss in 18-49 year old men. Dermatol Surg 1998;24(12):1330-2.
2. Norwood OT. Incidence of female androgenetic alopecia (female pattern alopecia). Dermatol Surg 2001;27(1):53-4.
3. Paik JH, Yoon JB, Sim WY, Kim BS, Kim NI. The prevalence and types of androgenetic alopecia in Korean men and women. Br J Dermatol 2001;145(1):95-9.
4. Heilmann-Heimbach S, Hochfeld LM, Paus R, Nöthen MM. Hunting the genes in male-pattern alopecia: how important are they, how close are we and what will they tell us? Exp Derma- tol 2016;25(4):251-7.
5. Tosti A, Iorizzo M, Piraccini BM. Androgenetic alopecia in children: report of 20 cases. Br J Dermatol 2005;152(3):556-9.
6. Sperling LC, Sinclair RD, Shabrawi-Caelen LE: Alopecias. In Bolognia JL, Schaffer JV, Cerroni L (eds): Dermatology. Forth Edition. Elsevier, 2018. pp. 1162-87.
7. Imperato-McGinley J, Zhu YS. Androgens and male physio- logy the syndrome of 5alpha-reductase-2 deficiency. Mol Cell Endocrinol 2002;198(1-2):51-9.
8. Sawaya ME, Price VH. Different levels of 5alpha-reductase type I and II, aromatase, and androgen receptor in hair follicles of women and men with androgenetic alopecia. J Invest Derma- tol 1997;109(3):296-300.
9. Sawaya ME. Purification of androgen receptors in human sebocytes and hair. J Invest Dermatol 1992;98(6 Suppl):92S- 96S.
10. Garza LA, Liu Y, Yang Z, et al. Prostaglandin D2 inhibits hair growth and is elevated in bald skalpof men with androgenetic alopecia . Sci Transl Med 2012;4:126ra34
11. Schmidt JB, Lindmaier A, Trenz A, Schurz B, Spona J. Hor- mone studies in females with androgenic hairloss. Gynecol Obstet Invest 1991;31(4):235-9.
12. Yip L, Rufaut N, Sinclair R. Role of genetics and sex steroid hormones in male androgenetic alopecia and female pattern hair loss: an update of what we now know. Australas J Dermatol. 2011;52(2):81-8.
13. Norwood OT. Male pattern baldness: classification and inci- dence. South Med J 1975;68(11):1359-65.
14. Olsen EA. Female pattern hair loss. J Am Acad Dermatol 2001;45(3 Suppl):S70-80.
15. Ludwig E. Classification of the types of androgenetic alopecia (common baldness) occurring in the female sex. Br J Dermatol 1977;97(3):247-54.
16. Cash TF. The psychosocial consequences of androgenetic alopecia: a review of the research literature. Br J Dermatol 1999;141(3):398-405.
17. Arias-Santiago S, Gutiérrez-Salmerón MT, Castellote- Caballero L, Buendía-Eisman A, Naranjo-Sintes R. Androgene- tic alopecia and cardiovascular risk factors in men and women: a comparative study. J Am Acad Dermatol 2010;63(3):420-9.
18. Amoretti A, Laydner H, Bergfeld W. Androgenetic alopecia and risk of prostate cancer: a systematic review and meta- analysis. J Am Acad Dermatol 2013;68(6):937-43.
19. Keum N, Cao Y, Lee DH, et al. Male pattern baldness and risk of colorectal neoplasia. Br J Cancer 2016;114(1):110-7.
20. Hirsso P, Rajala U, Laakso M, et al. Health-related quality of life and physical well-being among a 63-year-old cohort of women with androgenetic alopecia; a Finnish population-based study. Health Qual Life Outcomes 2005;3:49.
21. Inui S. Trichoscopy for common hair loss diseases: algorithmic method for diagnosis. J Dermatol 2011;38(1):71-5.
22. Olsen EA, Messenger AG, Shapiro J, et al. Evaluation and treatment of male and female pattern hair loss. J Am Acad Dermatol 2005;52(2):301-11.
23. Horenstein MG, Jacob JS. Follicular streamers (stelae) in scarring and non-scarring alopecia. J Cutan Pathol 2008;35(12):1115-20.
24. Whiting DA. Diagnostic and predictive value of horizontal sections of scalp biopsy specimens in male pattern androgenetic alopecia. J Am Acad Dermatol 1993;28:755-63.
25. Chitalia J, Dhurat R, Goren A, et al. Characterization of follicu- lar minoxidil sulfotransferase activity in a cohort of pattern hair loss patients from the Indian Subcontinent. Dermatol Ther 2018;31(6):e12688.
26. Lachgar S, Charveron M, Gall Y, Bonafe JL. Minoxidil upregu- lates the expression of vascular endothelial growth factor in human hair dermal papilla cells. Br J Dermatol 1998;138(3):407-11.
27. Olsen EA, Whiting D, Bergfeld W, et al. A multicenter, rando- mized, placebo-controlled, double-blind clinical trial of a novel formulation of 5% minoxidil topical foam versus placebo in the treatment of androgenetic alopecia in men. J Am Acad Derma- tol 2007;57(5):767-74.
28. Olsen EA, Dunlap FE, Funicella T, et al. A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol 2002;47(3):377-85.
29. van Zuuren EJ, Fedorowicz Z, Schoones J. Interventions for female pattern hair loss. Cochrane Database Syst Rev 2016;2016(5):CD007628.
30. Bergfeld W, Washenik K, Callender V, et al. A Phase III, Multicenter, Parallel-Design Clinical Trial to Compare the Effi- cacy and Safety of 5% Minoxidil Foam Versus Vehicle in Wo- men With Female Pattern Hair Loss. J Drugs Dermatol 2016;15(7):874-81.
31. Ramos PM, Sinclair RD, Kasprzak M, Miot HA. Minoxidil 1 mg oral versus minoxidil 5% topical solution for the treat- ment of female-pattern hair loss: A randomized clinical trial. J Am Acad Dermatol 2020;82(1):252-253.
32. Kaufman KD, Olsen EA, Whiting D, et al. Finasteride in the treatment of men with androgenetic alopecia. Finasteride Male Pattern Hair Loss Study Group. J Am Acad Dermatol 1998;39:578-89.
33. Price VH, Roberts JL, Hordinsky M, et al. Lack of efficacy of finasteride in postmenopausal women with androgenetic alope- cia. J Am Acad Dermatol 2000;43:768-76.
34. Yeon JH, Jung JY, Choi JW, et al. 5 mg/day finasteride treat- ment for normoandrogenic Asian women with female pattern hair loss. J Eur Acad Dermatol Venereol 2011;25(2):211-4.
35. Trüeb RM; Swiss Trichology Study Group. Finasteride treat- ment of patterned hair loss in normoandrogenic postmenopau- sal women. Dermatology 2004;209(3):202-7.
36. Mella JM, Perret MC, Manzotti M, Catalano HN, Guyatt G. Efficacy and safety of finasteride therapy for androgenetic alo- pecia: a systematic review. Arch Dermatol 2010;146(10):1141- 50.
37. Irwig MS, Kolukula S. Persistent sexual side effects of finaste- ride for male pattern hair loss. J Sex Med 2011;8(6):1747-53.
38. Rahimi-Ardabili B, Pourandarjani R, Habibollahi P, Mualeki A. Finasteride induced depression: a prospective study. BMC Clin Pharmacol 2006;6:7.
39. Klein EA, Tangen CM, Goodman PJ, Lippman SM, Thompson IM. Assessing benefit and risk in the prevention of prostate cancer: the prostate cancer prevention trial revisited. J Clin On- col 2005;23(30):7460-6.
40. Kjærulff TM, Ersbøll AK, Green A, et al. Finasteride Use and Risk of Male Breast Cancer: A Case-Control Study Using Indi- vidual-Level Registry Data from Denmark, Finland, and Sweden. Cancer Epidemiol Biomarkers Prev 2019;28(5):980- 986.
41. Lehrer S. Finasteride for postmenopausal breast cancer preven- tion. Eur J Cancer Prev 2015;24(5):456-7.
42. Hajheydari Z, Akbari J, Saeedi M, Shokoohi L. Comparing the therapeutic effects of finasteride gel and tablet in treatment of the androgenetic alopecia. Indian J Dermatol Venereol Leprol 2009;75(1):47-51.
43. Olsen EA, Hordinsky M, Whiting D, et al; Dutasteride Alope- cia Research Team. The importance of dual 5alpha-reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of dutasteride versus fi- nasteride. J Am Acad Dermatol 2006;55(6):1014-23.
44. Eun HC, Kwon OS, Yeon JH, et al. Efficacy, safety, and tole- rability of dutasteride 0.5 mg once daily in male patients with male pattern hair loss: a randomized, double-blind, placebo- controlled, phase III study. J Am Acad Dermatol 2010;63(2):252-8.
45. Olszewska M, Rudnicka L. Effective treatment of female androgenic alopecia with dutasteride. J Drugs Dermatol 2005;4(5):637-40.
46. Rathnayake D, Sinclair R. Innovative use of spironolactone as an antiandrogen in the treatment of female pattern hair loss. Dermatol Clin 2010;28(3):611-8.
47. Famenini S, Slaught C, Duan L, Goh C. Demographics of women with female pattern hair loss and the effectiveness of spironolactone therapy. J Am Acad Dermatol 2015;73(4):705- 6.
48. Yazdabadi A, Green J, Sinclair R. Successful treatment of female-pattern hair loss with spironolactone in a 9-year-old girl. Australas J Dermatol 2009;50(2):113-4.
49. Camacho-Martínez FM. Hair loss in women. Semin Cutan Med Surg 2009;28(1):19-32.
50. Vexiau P, Chaspoux C, Boudou P, et al. Effects of minoxidil 2% vs. cyproterone acetate treatment on female androgenetic alopecia: a controlled, 12-month randomized trial. Br J Derma- tol 2002;146(6):992-9.
51. Fabbrocini G, Cantelli M, Masarà A, et al. Female pattern hair loss: A clinical, pathophysiologic, and therapeutic review. Int J Womens Dermatol 2018;4(4):203-211.
52. Paradisi R, Porcu E, Fabbri R, et al. Prospective cohort study on the effects and tolerability of flutamide in patients with fe- male pattern hair loss. Ann Pharmacother 2011;45(4):469-75.
53. Ocampo-Garza J, Griggs J, Tosti A. New drugs under investi- gation for the treatment of alopecias. Expert Opin Investig Drugs 2019;28(3):275-284.
54. Sovak M, Seligson AL, Kucerova R, et al. Fluridil, a rationally designed topical agent for androgenetic alopecia: first clinical experience. Dermatol Surg 2002;28(8):678-85.
55. Valente Duarte de Sousa IC, Tosti A. New investigational drugs for androgenetic alopecia. Expert Opin Investig Drugs 2013;22(5):573-89.
56. Blume-Peytavi U, Lönnfors S, Hillmann K, Garcia Bartels N. A randomized double-blind placebo-controlled pilot study to as- sess the efficacy of a 24-week topical treatment by latanoprost 0.1% on hair growth and pigmentation in healthy volunteers with androgenetic alopecia. J Am Acad Dermatol 2012;66(5):794-800.
57. Emer JJ, Stevenson ML, Markowitz O. Novel treatment of female-pattern androgenetic alopecia with injected bimatoprost 0.03% solution. J Drugs Dermatol 2011;10(7):795-8.
58. Piérard-Franchimont C, De Doncker P, Cauwenbergh G, Piérard GE. Ketoconazole shampoo: effect of long-term use in androgenic alopecia. Dermatology 1998;196(4):474-7.
59. Fischer TW, Trüeb RM, Hänggi G, Innocenti M, Elsner P. Topical melatonin for treatment of androgenetic alopecia. Int J Trichology 2012;4(4):236-45.
60. Jo SJ, Shin H, Park YW, et al. Topical valproic acid increases the hair count in male patients with androgenetic alopecia: a randomized, comparative, clinical feasibility study using pho- totrichogram analysis. J Dermatol 2014;41(4):285-91.
61. Zimber MP, Ziering C, Zeigler F, et al. Hair regrowth following a Wnt- and follistatin containing treatment: safety and efficacy in a first-in-man phase 1 clinical trial. J Drugs Dermatol 2011;10(11):1308-12.
62. Harel S, Higgins CA, Cerise JE, et al. Pharmacologic inhibition of JAK-STAT signaling promotes hair growth. Sci Adv 2015;1(9):e1500973.
63. Jimenez JJ, Wikramanayake TC, Bergfeld W, et al. Efficacy and safety of a low-level laser device in the treatment of male and female pattern hair loss: a multicenter, randomized, sham device-controlled, double-blind study. Am J Clin Dermatol 2014;15(2):115-27.
64. Kelly Y, Blanco A, Tosti A. Androgenetic Alopecia: An Upda- te of Treatment Options. Drugs 2016;76(14):1349-64.
65. Lee GY, Lee SJ, Kim WS. The effect of a 1550 nm fractional erbium-glass laser in female pattern hair loss. J Eur Acad Der- matol Venereol 2011 Dec;25(12):1450-4.
66. Fertig RM, Gamret AC, Cervantes J, Tosti A. Microneedling for the treatment of hair loss? J Eur Acad Dermatol Venereol 2018;32(4):564-569.
67. Mysore V. Mesotherapy in management of hairloss - Is it of any use? Int J Trichology 2010;2(1):45-6.
68. Alves R, Grimalt R. Randomized placebo-controlled, double- blind, half-head study to assess the efficacy of platelet-rich plasma on the treatment of androgenetic alopecia. Dermatol Surg 2016;42(4):491-7.
69. Mapar MA, Shahriari S, Haghighizadeh MH. Efficacy of platelet-rich plasma in the treatment of androgenetic (male- patterned) alopecia: A pilot randomized controlled trial. J Cos- met Laser Ther 2016;18(8):452-455.
70. Rose PT. The latest innovations in hair transplantation. Facial Plast Surg 2011;27(4):366-77.
71. Harel S, Higgins CA, Cerise JE, et al. Pharmacologic inhibition of JAK-STAT signaling promotes hair growth. Sci Adv 2015;1(9):e1500973.
72. Shin H, Ryu HH, Kwon O, Park BS, Jo SJ. Clinical use of conditioned media of adipose tissue-derived stem cells in fema- le pattern hair loss: a retrospective case series study. Int J Der- matol 2015;54(6):730-5.
73. Leavitt M, Perez-Meza D, Rao NA, et al. Effects of finasteride (1 mg) on hair transplant. Dermatol Surg 2005;31(10):1268-76, discussion 1276.
74. Epstein JS. The treatment of female pattern hair loss and other applications of surgical hair restoration in women. Facial Plast Surg Clin North Am 2004;12(2):241-7.
75. Khandpur S, Suman M, Reddy BS. Comparative efficacy of various treatment regimens for androgenetic alopecia in men. J Dermatol 2002;29(8):489-98.

APA	Şahin G, Özdemir H, AYDİN F (2021). Androgenetik Alopesi. , 141 - 149. 10.32708/uutfd.857676
Chicago	Şahin Gökhan,Özdemir Hilal,AYDİN Fatma Androgenetik Alopesi. (2021): 141 - 149. 10.32708/uutfd.857676
MLA	Şahin Gökhan,Özdemir Hilal,AYDİN Fatma Androgenetik Alopesi. , 2021, ss.141 - 149. 10.32708/uutfd.857676
AMA	Şahin G,Özdemir H,AYDİN F Androgenetik Alopesi. . 2021; 141 - 149. 10.32708/uutfd.857676
Vancouver	Şahin G,Özdemir H,AYDİN F Androgenetik Alopesi. . 2021; 141 - 149. 10.32708/uutfd.857676
IEEE	Şahin G,Özdemir H,AYDİN F "Androgenetik Alopesi." , ss.141 - 149, 2021. 10.32708/uutfd.857676
ISNAD	Şahin, Gökhan vd. "Androgenetik Alopesi". (2021), 141-149. https://doi.org/10.32708/uutfd.857676

APA	Şahin G, Özdemir H, AYDİN F (2021). Androgenetik Alopesi. Uludağ Üniversitesi Tıp Fakültesi Dergisi, 47(1), 141 - 149. 10.32708/uutfd.857676
Chicago	Şahin Gökhan,Özdemir Hilal,AYDİN Fatma Androgenetik Alopesi. Uludağ Üniversitesi Tıp Fakültesi Dergisi 47, no.1 (2021): 141 - 149. 10.32708/uutfd.857676
MLA	Şahin Gökhan,Özdemir Hilal,AYDİN Fatma Androgenetik Alopesi. Uludağ Üniversitesi Tıp Fakültesi Dergisi, vol.47, no.1, 2021, ss.141 - 149. 10.32708/uutfd.857676
AMA	Şahin G,Özdemir H,AYDİN F Androgenetik Alopesi. Uludağ Üniversitesi Tıp Fakültesi Dergisi. 2021; 47(1): 141 - 149. 10.32708/uutfd.857676
Vancouver	Şahin G,Özdemir H,AYDİN F Androgenetik Alopesi. Uludağ Üniversitesi Tıp Fakültesi Dergisi. 2021; 47(1): 141 - 149. 10.32708/uutfd.857676
IEEE	Şahin G,Özdemir H,AYDİN F "Androgenetik Alopesi." Uludağ Üniversitesi Tıp Fakültesi Dergisi, 47, ss.141 - 149, 2021. 10.32708/uutfd.857676
ISNAD	Şahin, Gökhan vd. "Androgenetik Alopesi". Uludağ Üniversitesi Tıp Fakültesi Dergisi 47/1 (2021), 141-149. https://doi.org/10.32708/uutfd.857676